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Abstract
Background: Cancer stem cells/initiating cells (CSC/CIC), are thought to exist as a small population in malignant tissues.
They are resistant to conventional cancer treatments and possibly underlie post-treatment relapse. The CIC population can
be targeted with capsid modified oncolytic adenoviruses.
Methodology/Principal Findings: We studied the mechanisms of innate immunity to oncolytic adenovirus Ad5/3-Delta24 in
conventional treatment resistant non-CIC breast cancer cells, breast cancer CD44
+/CD24
2/low CIC population and normal
breast tissue CD44
+/CD24
2/low stem cells. We compared virus recognition by pattern recognition receptors for adenovirus,
Toll-like receptors (TLR) 2 and 9 and virus induced type I interferon (IFN) response regulation in these cell types. We show
TLR mediated virus recognition in these non-immune cell types. Normal tissue stem cells have intact type I IFN signaling.
Furthermore, TLR9 and TLR2 reside constantly in recognition sites, implying constant activation. In contrast, breast cancer
CD44
+/CD24
2/low CIC have dysregulated innate immune responses featuring dysfunctional virus recognition caused by
impaired trafficking of TLR9 and cofactor MyD88 and the absence of TLR2, having a deleterious impact on TLR pattern
recognition receptor signaling. Furthermore, the CIC have increased inhibitory signaling via the suppressor of cytokine
signaling/Tyro3/Axl/Mer receptor tyrosine kinase (SOCS/TAM) pathway. These defects in contribute to dysfunctional
induction of type I IFN response in CIC and therefore permissivity to oncolytic adenovirus.
Conclusions/Significance: CICs may underlie the incurable nature of relapsed or metastatic cancers and are therefore an
important target regarding diagnostic and prognostic aspects as well as treatment of the disease. This study addresses the
mechanisms of innate infection immunity in stem cells deepening the understanding of stem cell biology and may benefit
not only virotherapy but also immunotherapy in general.
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Introduction
Several cancer types have been shown to contain a small
population of cells that are resistant to conventional treatments and
may contribute to post-treatment relapse. This population possesses
a greater ability to maintain tumor formation than other tumor cell
types and shares metabolic properties and markers with normal
tissue specific stem cells. Therefore, these cells have been proposed
to be cancer initiating cells or so called cancer stem cells (CIC/
CSC). Normal stem cells allow the maintenance, regeneration and
growth of adult tissues and sustain a pool of undifferentiated tissue-
specific cells under regulation of local and systemic signals. In
contrast, CICs have lost this control [1]. Populations with CIC
properties have been identified in cancers of the hematopoietic
system, brain, breast, ovary and prostate [2,3]. In breast cancer, the
CIC population has been shown to lie in the CD44
+/CD24
2/low
portion [2,4,5]. The phenotypic properties associated with CIC are
slow cellular replication, the capacity for expelling anti-tumor drugs
and apoptosis resistance [6]. These characteristics render them
resistanttomanyconventionalcancertherapies[4,6,7,8].CICsmay
underlie the incurable nature of relapsed or metastatic cancers and
are therefore an important target regarding diagnostic and
prognostic aspects as well as treatment of the disease [9,10].
Capsid modified oncolytic adenoviruses can be utilized to
specifically target the CD44
+/CD24
2/low population [11,12,13,14].
Infection of tumor cells results in selective replication, oncolysis, and
subsequent release of the virus progeny through vasculature into
metastases. Normal tissue is spared due to engineered alterations in
the virus genome [12]. These viruses are emerging as novel tools for
cancer therapy and several are already in clinical trials [15,16].
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and chemotherapy and also as tools for immunotherapy [17]. Thus,
oncolytic viruses have significant advantages for improving treatment
options for patients [18].
The innate immune responses, mediated by type I interferons
(IFN) and cytokines such as IL6 and TNF-a, are key in defining
permissivity of different cell types to viral infection. These
phenomena are well characterized in immune cells whereas still
poorly understood in the context of stem cells. Normal tissue stem
cells display resistance to viral infection whereas the CIC containing
population appears permissive to viral infection by oncolytic viruses
[11,19,20,21]. Several cytokines modulate CIC functions and
understanding these interactions is central in targeting the cancer
cell population [22]. Variable defects in interferon response may
confer cancer cells a growth or survival advantage. However,
dysfunction in interferon production or responsiveness to interfer-
ons results in a compromised antiviral response.
Virus-induced type I IFN response is mediated by type I IFN
receptor (IFNAR), interferon regulatory transcription factors (IRFs)
and transcription factor NFkB. A second signaling pathway involves
Toll-like receptors (TLRs) that are expressed on the cell surface or in
endosomes. TLRs signal through adaptor proteins including MyD88,
TRIF and TRAF6 [23] activating signal cascades employing the
MAP kinase, NFkB and IRF. The main pathogen pattern
recognition receptors (PPRs) for adenoviruses are TLR9 in the
endosomes and TLR2 on the cell surface [24,25]. Both signal
MyD88-dependently activating NF-kB and MAPK cascades leading
to the production of type I IFNs inducing an antiviral state[26]. The
different routes of activation depend on the cell type. To limit
potentially harmful inflammation, responses are attenuated by
Tyro3/Axl/Mer (TAM) family of receptor tyrosine kinases. TAM
receptors act in conjunction with the IFNAR/STAT signaling
cassette driving the expression of suppressor of cytokine signaling
(SOCS) proteins that inhibit signaling via STAT and TLR pathways.
Previous data suggested that CD44
+/CD24
2/low CIC popula-
tions are more permissive to Ad5/3-Delta24 capsid modified
oncolytic adenovirus, than the cell population in the correspond-
ing normal tissue, and can be killed by oncolytic virus [11,13,21].
We have here studied whether this is caused by dysregulation of
innate immune responses. We explore innate immunity pathways
in breast cancer CIC and compare them to non-CIC but
treatment resistant breast cancer cells and normal mammary
tissue cells. This study broadens the understanding of innate
immunity in normal breast stem cells and the cancer initiating
population. Modulation of these pathways may improve viral
oncolytic efficacy in cancer stem cell targeting cancer therapy.
Results
Characterization of cell populations in normal breast
tissue derived mammospheres and breast cancer patient
pleural effusion explant derived JIMT-1 and ArLa
Cells isolated from normal mammary tissue cultured in vitro and
two conventional cancer treatment resistant breast cancer patient
Figure 1. Characterization of normal breast tissue mammosphere, JIMT-1 and ArLa breast cancer patient pleural effusion explant
derived cell line stem cell populations. To characterize the distribution of prospective stem cell/cancer stem cell populations normal breast
tissue derived mammospheres grown in stem cell enriching conditions (A, arrowheads) and JIMT-1 breast cancer patient pleural effusion explant
derived cell line were immunostained with a undifferentiated stem cell marker Oct3/4 and mammary stem cell marker Musashi, nucleai stained with
DAPI (blue, A–C). (A and B) Mammospheres show positivity for Oct3/4 (red) and Mushashi (green). (C) JIMT-1 breast cancer patient pleural effusion
explant derived cell line similarly shows positivity for Oct3/4 (red) and also CD44+ (green). Scale bars: A 80 mm, B and C 20 mm (D) Distributions of
non-cancer initiating (non-CIC) populations CD44
2/CD24
2 and CD24+ and CIC/stem cell containing CD44
+/CD24
2/low population in mammospheres,
JIMT-1 and ArLa breast cancer cell lines (D).
doi:10.1371/journal.pone.0013859.g001
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analyzed for phenotypic properties. We have previously shown
that JIMT-1 CD44
+/CD24
2/low reconstitute tumors in vivo in a
xenograft mouse model [11]. Here we further analyzed universal
undifferentiated stem cell markers and CD44 and CD24 status to
identify proportions of prospective normal tissue stem cell/CIC
populations.
The cells isolated from normal mammary tissue formed self-
renewing spheroids in attachment independent conditions in the
absence of serum (Fig. 1A). These spheres could be passaged up to
four times and showed positivity for the undifferentiated stem cell
marker Oct3/4 and mammary stem cell marker Musashi (Figs. 1A
and B). Similarly, the JIMT-1 breast cancer patient pleural
effusion explant derived cells were positive for CD44 and Oct3/4
respectively (Fig. 1C). Mammospheres were enriched with of
CD44
+/CD24
-/low population containing 87% of this cell type
(Fig. 1D). The JIMT-1 were also enriched in CD44
+/CD24
2/low
containing 25% of the prospective CIC-population (Fig. 1D). In
contrast, the ArLa contained less than 1% CD44
+/CD24
2/low
cells (Fig. 1D) and were thus defined as the non-initiating (non-
CIC) cancer cell type.
Endogenous TLR9 resides persistently in endosomes in
CD44
+/CD24
2/low normal mammary tissue cells
TLR9 and TLR2 are specific pathogen recognition receptors of
adenovirus [24,25]. The localization of the innate immune sensors
at the cellular level is of key importance for their physiological
function and any misplacement may result in an impaired
Figure 2. TLR9 and TLR2 reside constantly in sites of virus recognition in normal breast tissue stem cells. (A) Immunofluorescence
staining of endogenous TLR9 (red) in normal mammary stem cells shows colocalization with an endosomal marker EEA1 (green) in both oncolytic
adenovirus Ad5/3-Delta24 infected cells at 6 h after infection and also non-infected cells (A), DAPI nuclear staining in blue. (B) Quantization of
colocalization: The graph represents Pearson’s coefficient of TLR9 and endosome (EE) colocalization from three independent fields of cells in two
different experiments. Colocalization of TLR9 to endosomal marker EEA1 (EE) shows no difference between infected and non-infected normal stem
cells (error bars SD, p=0.07) (B). Endogenous TLR2 staining (red) in normal stem cells shows cell surface and partly endosomal distribution in both
infected and non-infected cells (C). Endogenous MyD88 (red), a cofactor in TLR signaling, is present in infected cells and associates with endosomal
structures (green), DAPI in blue (D). The distributions of the pathogen pattern recognition receptors in mammospheres suggest constant activation of
the receptors in this cell type (C). Scale bar:10 mm.
doi:10.1371/journal.pone.0013859.g002
Breast Cancer Innate Immunity
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e13859Breast Cancer Innate Immunity
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e13859response. We hypothesized that mislocalization of these receptors
in mammary tissue CD44
+/CD24
2/low stem cells and/or CIC can
result in an impaired immune response. Therefore, we analyzed
the localization of endogenous TLR9, TLR2 and cofactor MyD88
by immunofluorescence staining and confocal microscopy in
sorted non-infected cells and cells sorted and infected with a
chimeric oncolytic adenovirus bearing the knob domain of the
adenovirus serotype 3 (Ad5/3-Delta24).
In normal mammary tissue CD44
+/CD24
2/low stem cells
TLR9 localized in endosomes in Ad5/3-Delta24 infected cells,
as indicated by colocalization with an endosomal marker EEA1
and persisted still in the endosomes 6 h after infection (Figs. 2A,
B). Interestingly TLR9 and TLR2 were found in the endosomes
also in uninfected normal mammary tissue CD44
+/CD24
2/low
stem cells cells (Figs. 2A-C) suggesting constant activation of the
receptors in this cell type. Colocalization analysis of TLR9 and
EEA1 in showed a similar pattern in both infected and non-
infected cells (Fig. 2B). The cofactor of TLR2 and TLR9 signaling
MyD88 was also found to be associated with endosomes in
infected CD44
+/CD24
2/low normal mammary tissue cells
(Fig. 2D).
Virus recognition by TLR9 and TLR2 in ArLa non-CIC and
mislocalization of endogenous TLR9 and absence of
endogenous TLR2 in JIMT-1 CD44
+/CD
242/low CIC
Endogenous TLR9 and TLR2 were next studied in Ad5/3-
Delta24 infected and non-infected non-CIC ArLa cells and JIMT-
1 CD44
+/CD24
2/low CIC by immunofluorescence staining and
confocal microscopy. Staining of adenovirus hexon showed that
the virus could infect both CD44
+/CD24
2/low JIMT-1 and ArLa,
as positive staining was initially seen on cell surfaces and at later
time points at 30 min up to 4 h internalized in endosomes
(Figs. 3A-C and 4A-C). In non-infected non-CIC ArLa cell low
level of TLR9 expression was seen localized in the ER and upon
infection TLR9 was upregulated and localized in endosomes,
indicating normal trafficking of the protein (Fig. 3A). Also,
adenovirus staining colocalized with TLR9 in endosomes
(Fig. 3B) and with TLR2 on the cell surface (Fig. 3C) indicating
that in this breast cancer cell type TLR9 and TLR2 are active in
virus recognition.
In non-infected JIMT-1 CD44
+/CD24
2/low low levels of TLR9
were present in the ER (Fig. 4A). However, in contrast to normal
tissue CD44
+/CD24
2/low stem cells and ArLa non-CIC, in
infected JIMT-1 CD44
+/CD24
2/low CICs endogenous TLR9 was
mislocalized in ER-Golgi like structures and not in endosomes
(Fig. 4A and B) and also did not colocalize with adenovirus in the
endosomes (Fig. 4B and C) indicating dysregulated trafficking and
dysfunctional virus recognition by TLR9. The trafficking of TLR9
in JIMT-1 CD44
-/CD24
- non-CIC population showed a similar
pattern as ArLa non-CIC: The receptor was found in the ER and
at low levels in endosomes in non-infected cells (Fig. 5A) and upon
infection TLR9 was upregulated and trafficked from the ER to the
endosomes (Fig. 5 B and C). In contrast to normal stem cells and
ArLa non-CIC cells, TLR2 was undetectable or severely reduced




Colocalization analysis of TLR9 and MyD88 to ER or
endosomes in JIMT-1 CD44
+/CD24
2/low CICs showed that
neither TLR9 nor MyD88 fully reaches endosomes in 4 h and 6 h
respectively (Fig. 6B), whereas in the CD44
2/CD24
2 non-CIC
population localization became endosomal upon virus infection
(Fig. 6B). Colocalization analysis of TLR9 to endosomal marker
EEA1 in infected ArLa non-CIC showed that TLR9 partially
colocalizes with endosomes at two hours and fully four hours after
infection (Fig. 6C). Colocalization analysis of TLR9 and TLR2 to
adenovirus in ArLa non-CIC verifies the recognition of adenovirus
by TLR9 and TLR2 in this cell type at respective time points
(Fig. 6D). In contrast TLR9 in JIMT-1 CD44
+/CD24
2/low CIC
does not colocalize with adenovirus staining (Fig. 6 D). In JIMT-1
CD44
2/CD24
2 non-CIC population the localization pattern of
TLR9 in respect to adenovirus was similar to non-CIC ArLa
(Fig. 6D). Defective trafficking of TLR9 and MyD88 in JIMT-1
CD44
+/CD24
2/low CIC was further confirmed by transient
transfection of constructs expressing fluorescently labeled proteins
and organelle markers with live cell imaging (Supplementary Fig. S1).
In conclusion, non-CIC breast cancer cells feature oncolytic
adenovirus recognition by TLR9 and TLR2 and intact TLR
trafficking, whereas CIC have defects in trafficking of TLR9 and
co-factor MyD88 and lack of TLR2. These defects are likely to
have an impact on the proper function on pathogen recognition
receptor signaling impairing innate immune responses in these
cells.
Defective IFN production in ArLa non-CIC and JIMT-1
CD44
+/24




As innate immune recognition of the oncolytic adenovirus
seemed to be compromised in CIC we next assayed type I IFN
production in response to virus infection by quantitative real time
PCR in CD44
+/CD24
2/low normal stem cells, ArLa non-CIC
cells and JIMT-1 CD44
+/CD24
2/low CICs. Cells were sorted and
infected with Ad5/3-Delta24 and four and 24 hours following
infection, mRNA was collected and analyzed for type I interferons
(IFNa and IFNb) interferon regulatory factors IRF3, IRF7 and
transcription factor STAT1 expression.
Normal mammary tissue CD44
+/CD24
2/low stem cells showed
a prominent innate immune response to infection with oncolytic
virus: 1.6 and 4.8 fold induction of IFNa at 4 h and 24 h time
points and 2.5 fold induction of IFNb at 4 h respectively were
detected (Fig. 7A). Interestingly only minor induction of IFNa (1.3
fold) at 4 h and IFNb (1.4 fold) at 24 h were detected in non-CIC
ArLa cells. and no induction of IFNb at 4 h and IFNa and
STAT1 at 24 h time points compared to non-infected cells
(Fig. 7A). Similarly, CD44
+/CD24
2/low CIC JIMT-1 cells showed
a minor induction of IFNb (1.2 fold) at 4 h but no induction of
IFNa or STAT1. Minor induction of IRF3 (1.6 fold) was detected
at 24 h whereas IRF7 could not be detected at this time point
Figure 3. Oncolytic adenovirus recognition by TLR9 and TLR2 in ArLa non-CIC breast cancer cells. Immunofluorescence staining of TLRs
in non-CIC ArLa breast cancer cells: (A) In non-infected non-CIC ArLa low level of TLR9 staining (red) is present and upon infection with Ad5/3-Delta24
oncolytic adenovirus TLR9 is upregulated and the localization becomes endosomal, as indicated by colocalization with endosomal marker EEA1
(green), indicating normal trafficking of the receptor. (B) Staining of adenovirus hexon (red) in infected ArLa cells at 0 min, 30 min, 1 h and 4 h time
points following infection, shows initial localization of the virus on cell surfaces and at later time points at 30 min up to 4 h internalization in
endosomes (EEA1, green). Nuclear counterstain (DAPI) in white. (B) Furthermore, adenovirus staining (red) colocalizes with TLR9 (blue) in endosomes
(green). (C) Adenovirus staining (red) also colocalizes with TLR2 (green) in ArLa cells (DAPI in blue). These data indicate that in this non-CIC
conventional cancer treatment resistant breast cancer cell type TLR9 and TLR2 are active in oncolytic adenovirus recognition. Scale bars: 10 mm.
doi:10.1371/journal.pone.0013859.g003
Breast Cancer Innate Immunity
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+/
CD24
2/low stem cells produced an intact IFN response to virus
infection whereas both CD44
+/CD24
2/low CIC and non-CIC
population were defective in IFN production when infected with
an oncolytic adenovirus.
To verify if the defect in initiation of innate immune responses
in JIMT-1 CD44
+/CD24
2/low CIC, is due to dysfunction in
responsiveness to autocrine/paracrine type I IFNs in addition to
dysfunction in the initial recognition step, we next studied type I
IFN response induction by exogenous IFN in JIMT-1 CD44
+/
CD24
2/low CIC. The cells were primed with recombinant
universal type I interferon prior to infection with Ad5/3-Delta24
or receptor signaling was blocked by interferon receptor
neutralizing antibody. IFN induction in pretreated cells in
response virus infection was assayed by quantitative real time
PCR. Exogenous IFN induced induction of IFNa (13.0 fold), IFNb
(7.2) and STAT1 (7.8 fold) was seen at 4 h (Fig. 7B). However, this
induction was rapidly decreased and at 24 h point IFNa, IFNb
and STAT1 levels returned to baseline (Fig. 7B). The exogenous
induction of type I IFN was inhibited by treatment with receptor
neutralizing antibody (Fig. 7B). In conclusion, JIMT-1 CD44
+/
CD24
2/low are able at least to a limited extent to respond to
exogenous IFN, however they have a dysfunction in initiation of
endogenous type I IFN response upon virus infection.
STAT activation in type I IFN response regulation upon
virus infection
To explore STAT activation in type I IFN response regulation
in ArLa non-CIC cells and JIMT-1 CIC and non-CIC cell
populations the cells were sorted and infected with oncolytic
adenovirus Ad5/3-Delta24 and STAT1 and STAT3 expression
and activation were assayed by Western blot at different time
points. ArLa non-CIC cells showed constant activation of STAT1
in infected and non-infected cells (Fig. 8A). There was also
constant activation of STAT3 (Fig. 8B). In contrast, in JIMT-1
CD44
+/CD24
2/low CIC and CD44
2/CD24
2 non-CIC no active
STAT1 was detected (Fig. 8B). In addition, in the JIMT-1
CD44
2/CD24
2 non-CIC population expression of both STAT1
and STAT3 decreased 60 min after infection and no more P-
STAT3 could be detected at this time point. However, we
observed some degree of STAT3 activation at all time points in the
CIC population (Fig. 8B). ArLa non-CIC cells treated with
recombinant exogenous IFN showed no change in STAT3
expression or phosphorylation status (Fig. 8C).
In conclusion, defects present in ArLa non-CIC and JIMT-1
CIC type I IFN production may be explained by two different
mechanisms: In ArLa constitutive STAT activation represses
induction of type I IFN response, whereas in JIMT-1 initial defects
are present already at the step of virus recognition.
SOCS and TAM receptors in response to oncolytic
adenovirus infection
To characterize the role of inhibitory SOCS and TAM-receptor
signaling in innate immunity regulation, ArLa non-CIC cells and
JIMT-1 CIC and non-CIC cell populations were infected with
oncolytic adenovirus Ad5/3-Delta24, SOCS1, SOCS3 and Axl,
Mer and Tyro3 expression were analyzed by Western blot. The
ArLa non-CIC cells showed upregulation of the expression of both
SOCS1 and SOCS3 at the 2 h time point but they were no longer
detectable at later time points (Fig. 9A). In contrast, there was
constant expression of SOCS1 in both infected and non-infected
JIMT-1 CD44
+/CD24
2/low CIC infected and non-infected and
infected CD44
2/CD24
2 non-CIC populations at all time points
(Fig. 9B) and no expression or minor expression of SOCS3 in both
populations (Fig. 9B).
No Axl, Mer or Tyro3 induction was seen in ArLa non-CIC
(Fig. 9C). Interestingly, JIMT-1 CD44
+/CD24
2/low CIC show
constant upregulation of Axl, Mer and Tyro3 (Fig. 9D). In infected
JIMT-1 non-CIC CD24
+ population constant Mer expression, but
no Axl expression was seen (Fig. 9D).
Discussion
Increasing evidence suggests that various conventional treat-
ment resistant cancer cell types, including cancer initiating cells,
can be targeted by oncolytic viruses. Viruses are not sensitive to
drug resistance mechanisms and can overcome defective apoptotic
signaling [27]. Our approach utilizes breast cancer patient pleural
effusion explant derived cells to model the hierarchical progression
of cancer and/or intratumoral heterogeneity. Both ArLa and
JIMT-1 represent highly treatment resistant cancer types, the
latter featuring also an enrichment of the CD44
+/CD24
2/low
containing the CIC cell types. Previous data shows that capsid
modified adenoviruses can be used to efficiently target this cell
population in vitro and in vivo [11,13]. However, as all adult humans
have sustained wild type adenovirus infections, normal tissue stem
cells must have resistance to viral infection. The mechanisms
underlying the differences in sensitivity of CIC versus normal stem
cells to viral oncolysis have not been studied before.
Various defects in IFN responses confer survival advantages to
cancer cells while also resulting in compromised antiviral response.
A recent report implicates novel gene sets in oncogenic Ras, TNF
and IFN pathways in breast cancer CD44
+/CD24
2/low popula-
tions [28]. We show on a functional level that CD44
+/CD24
2/low
CIC have defective innate immunity IFN responses while normal
mammary tissue cells produce robust responses. Previous reports
with other oncolytic viruses show that activation of the interferon
pathway protects normal cells while maintaining the vulnerability
of cancer cells. For example IFNa or a synthetic inducer of the
IFNa/b pathway poly(I:C) completely attenuated oncolytic
Vesicular stomatitis virus (VSV) infection of normal brain cells
of variable origin, whereas glioblastoma cell lines treated
identically were killed by VSV [29]. This indicates that normal
stem cells are protected from oncolytic viruses due to intact IFN
signaling whereas malignant cells succumb to oncolysis.
PRRs are specialized for sensing pathogen-associated molecular
patterns such as viral nucleic acids to induce innate immune
responses [30,31]. Most non-immune cells rely specifically on
PPRs to sense infection. Detection via PPRs involves diverse
Figure 4. Mislocalization of TLR9 in JIMT-1 CD44
+/CD24
2/low CIC breast cancer cells. In contrast to normal tissue stem cells and ArLa non-
CIC cancer cells, TLR9 (red) shows mislocalization in JIMT-1 CD44
+/CD24
2/low CIC population indicated by distinct distribution form the endosomal
marker EEA1 (green) and partial co-localization with an ER-marker calnexin (ER, green) in both infected or non-infected cells, nuclear stain DAPI in
blue (A). (B and C) Staining of adenovirus hexon (red) at 0 min, 30 min, 1 h and 4 h time points following infection, shows initial localization of the
virus on cell surfaces and at later time points at 30 min up to 4 h internalization in endosomes, showing that Ad5/3-Delta24 is able to infect this cell
type. DAPI nuclear staining in white (B and C). In infected JIMT-1 CD44
+/CD24
2/low CIC TLR9 (blue) is retained in the ER-golgi like structures (B, green)
and does not traffic to the endosomes (C, green) to colocalize with the virus at time points up to 4 h post infection (B). Scale bars:10 mm.
doi:10.1371/journal.pone.0013859.g004
Breast Cancer Innate Immunity
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utilized to circumvent the inherent resistance of cancer cells to
current cancer treatments. Inherent defects in specifically the
breast cancer CIC population PPRs TLR2 and TLR9 are likely to
contribute to dysfunction in the initiation of the type I IFN
response leading to a failure of feed-forward signal amplification
via IRFs and STAT signaling. This further impacts inhibitory
signaling as illustrated by increase of TAM receptors, driven by
either inherent upregulation or defects in STAT-SOCS signaling
as a compensatory mechanism. On the other hand we also show
that while the non-CIC but treatment resistant cells recognize
adenovirus by TLR9 and TLR2 have intact PPR signaling per se,
they still are defective in IFN signaling. This is most probably due
to the hyperactivation of STAT3 and/or decreased SOCS
expression mediated silencing of cytokine and chemokine
production as reported previously in the context of other types
of cancer cells [32]. Constitutively activated STAT3 enhances
tumor cell proliferation and prevents apoptosis [33]. This also
induces the release of factors that inhibit dendritic cell maturation
through activation of STAT3 in dendritic cells, negatively
regulating induction of adaptive immunity [32].
Non-CIC cancer cells are also unresponsive to exogenous IFN,
causing deficiency in paracrine activation. STAT1 is directly
suppressed upon adenoviral infection by viral E1A [34]. We used a
partly E1A deleted virus, so this interaction may also play a role in
downregulation of type I IFN responses even though the CIC
population show deficient STAT1 activation. However, constitu-
tive SOCS1 expression and increase in TAM receptor expression
in CIC may partly be driven by interaction with viral proteins.
Taken together both the CIC and non-CIC conventional
treatment resistant populations are defective in type I IFN
signaling inducing permissivity to infection. However, this is
caused by different mechanisms in each cell population. The
mechanisms of viral permissivity in CIC, explored in this study,
could further be utilized as prognostic markers, for example
looking at primary components or expression levels of downstream
targets of the affected pathways.
Strictly controlled cellular localization and trafficking are crucial
for the proper function of PPRs in initializing anti-viral responses
and avoiding autoimmune reactions. In immune cells TLR9 is
expressed at low levels and sequestered in the endoplasmic
reticulum (ER) before stimulation. Upon ligand stimulation, it
traffics from the ER to the endolysosomes where it binds
internalized DNA and initiates a signaling cascade via MyD88
[35,36,37]. Moreover, the stimulation results in rapid upregulation
of the expression in a positive feedback manner. Interestingly, we
show here in normal breast stem cells localization of TLR9 and
TLR2 in the sites of recognition, endosomes and cell surface
respectively, even without stimulation. This implies constant
activation of the receptors and might therefore help explain
normal stem cell resistance to wild type virus infection. Moreover,
we show for the first time active virus recognition by TLRs in non-
immune cell types.
It is possible that, however compromised, the innate immune
response might confer resistance against oncolytic viruses to some
CIC types. This would partly explain the observed preclinical and
clinical findings where tumors were reduced but not completely
eradicated or there was a relapse after viral treatment [13]. The
presence of highly treatment resistant but differentiated tumor cells
could also contribute to this. On the other hand, the type I IFN
response induced in the tumor after virus infection could represent
an advantage for immunotherapy, where CIC could act as co-
adjuvant for the therapeutics.
In summary, this study addresses the mechanisms of innate
infection immunity in stem cells, a field which has so far been
unexplored. The findings deepen the understanding of stem cell
biology and may benefit not only virotherapy but also immuno-
therapy in general.
Materials and Methods
Clinical samples and Cell Culture
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Helsinki University Central
Hospital. All patients provided written informed consent for the
collection of samples and subsequent analysis.
Cells were isolated from breast tissue derived from reduction
mammaplasties. The tissues were dissociated manually and treated
with Blenzyme1 collagenase-dispase cocktail 18 h at +37uC
strained consecutively through cell strainers, red blood cell lysis
was performed and the cells further incubated in Accumax (PAA)
to produce single cells. Cells were maintained in MEGM medium
with Bullet Kit supplements (Gibco), 1 ml/ml Gentamicin (Sigma)
and 1 mg/ml Fungizone/Amphotericin B (Sigma). Cell singularity
was confirmed with microscopy and cells were amplified in
adherence independent conditions on ultra low-attachment plates
(Corning) in reducing amount of FCS to generate spheres.
Cancer cell lines were derived from breast cancer patient
pleural effusion derived cells. JIMT-1 (Tanner et al. 2004) are
estrogen receptor (ER) and progesterone receptor (PR) negative
and human epidermal growth factor receptor 2 (HER-2) positive
and ArLa (Courtesy of M. Tanner, Institute of Medical
Technology, Tampere University and Tampere University
Hospital) ER, PR and HER-2 negative. JIMT-1 were cultured
in DMEM/F12 with human recombinant insulin 1 mg/ml (Sigma)
2 mM L-glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin
and 10% FCS (Lonza) and ArLa in RPMI-1640 supplemented
with antibiotics and 10% FCS (Lonza). For isolation of cell
populations the cells were sorted with fluorescein isothiocyanate–
labeled anti-CD44 and phycoerythrin-labeled anti-CD24 antibod-
ies (BD Pharmingen, Franklin Lakes, NJ), which were collected
with fluorescein isothiocyanate- and phycoerythrin-conjugated
magnetic beads, respectively (Miltenyi Biotech, Bergisch Glad-
bach, Germany). HeLa were maintained in DMEM supplemented
with antibiotics and 10% FCS. Jurkat (A3) cells were acquired
from ATCC and cultured in RPMI-1640 containing the same
supplements.
Oncolytic adenovirus
The oncolytic adenovirus used in the study is replication
competent Ad5/3-Delta24 [38,39]. It is a serotype 5 based virus
Figure 5. Normal trafficking of TLR9 in JIMT-1 CD44
2/CD24
2 non-CIC population. Immunofluorescence staining of TLR9 in JIMT-1 CD44
2/
CD24
2 non-CIC population. (A) In non-infected non-CIC cells TLR9 (red) resides partially in endosomes and ER (EEA1 and ER, both in green). (B and C)
Adenovirus staining (red) in infected JIMT-1 non-CIC population at 0 min, 30 min, 1 h and 4 h time points following infection, shows the virus on cell
surfaces and internalized in endosomes (EEA1, green) together with TLR9 (blue). TLR9 is upregulated upon infection and shows intact trafficking from
the ER to the endosomal compartment (C). Nuclear counterstain (DAPI) in white. These data indicate that, in contrast to the cancer initiating
population of JIMT-1, the non-CIC CD44
2/CD24
2 cell types show intact trafficking and adenovirus recognition by TLR9. Scale bars: 10 mm.
doi:10.1371/journal.pone.0013859.g005
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PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e13859Figure 6. Absence of TLR2 and dysregulated trafficking of TLR9 in JIMT-1 CD44
+/CD24
2/low CIC breast cancer cells. (A)
Immunofluorescence staining of TLR2 (red) in JIMT-1 CD44
+/CD24
2/low CIC population shows absence of the receptor in non-infected and infected
cells, DAPI nuclear staining in blue. (B) Colocalization analysis of organelle markers to TLR9 and MyD88 in JIMT-1 CD44
+/CD24
2/low CIC and JIMT-1
CD44
2/CD24
2 non-CIC cell populations. Graphs represent Pearson’s coefficient of TLR9 and MyD88 colocalization to ER or endosomes (error bars:
SEM). In JIMT-1 CD44
+/CD24
2/low CIC TLR9 does not reach endosomes but remains colocalized with the ER up to four hours. Similarly, MyD88 does
not associate with endosomes at 6 h time point (C) indicating dysfunctional trafficking of the proteins. However, in JIMT- 1 CD44
2/CD24
2 non-CIC
cell population both TLR9 and MyD88 associate with endosomes two hours following infection. Colocalization analysis of TLR9 to endosomal marker
in ArLa non-CIC shows partial colocalization at two hours and full colocalization at four hours after infection (C). Colocalization analysis of TLR9 and
TLR2 to adenovirus in ArLa non-CIC verifies the recognition of adenovirus by TLR9 and TLR2 in this cell type (D). In contrast TLR9 in JIMT-1 CD44
+/
CD24
2/low CIC does not colocalize with adenovirus staining, whereas in CD44
2/CD24
2 non-CIC population TLR9 colocalizes with the adenovirus
staining similarly to ArLa non-CIC (D).
doi:10.1371/journal.pone.0013859.g006
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PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13859Figure 7. Intact type I IFN response in normal stem cells and defective type I IFN response in JIMT-1 CD44
+/CD24
2/low CIC and ArLa
non-CIC breast cancer cells. (A) Normal breast tissue derived mammospheres, ArLa non-CIC breast cancer cells and JIMT-1 CD44
+/CD24
2/low CIC
and were infected with an oncolytic adenovirus Ad5/3-Delta24 and total cellular RNA was collected at 4 h and 24 h after infection. RNA was isolated
for cDNA synthesis, and semiquantitative RT-PCR was performed to determine relative IFNa, IFNb, IRF3, IRF7 and STAT1 mRNA levels. Data are
representative of three individual experiments. (B) Type I IFN induction in JIMT-1 CD44
+/CD24
2/low CIC treated with recombinant universal type I
interferon and/or with interferon receptor neutralizing antibody and relative mRNA levels assayed by qPCR: Exogenous IFN results in induction of
IFNa, IFNb and STAT1 at 4 h and the levels are downregulated to baseline at 24 h. Induction is inhibited by receptor neutralizing antibody. These
results imply that the defect in innate immune response in CD44
+/CD24
2/low CIC is caused at least partly by dysfunctional virus recognition and
consecutive defect in response initiation but also to some extent limited responsiveness to autocrine/paracrine IFN.
doi:10.1371/journal.pone.0013859.g007
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PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e13859retargeted to the adenovirus serotype 3 receptor. The tumor
selectivity of Ad5/3-Delta24 is based on a 24 bp deletion in the
retinoblastoma (Rb) binding site of E1A [40,41]. The virus has
been shown to infect and kill CD44
+/CD24
2/low cells [11,13].
Relative mRNA quantitation by Real-Time PCR
Cells were infected with Ad5/3-Delta24 at multiplicity of infection
(moi) 100 VP/cell and total cellular RNA was isolated from cancer
cells or mammospheres derived from three pooled donors, using the
Qiagen RNeasy kit at different time point. Total cellular RNA (2 mg)
was reverse-transcribed into cDNA in TaqMan RT buffer with
1.25 U/mL MultiScribe RT (Applied Biosystems, Foster City, CA,
USA).cDNAsampleswereamplifiedinRocheuniversalPCRmaster
mix buffer (Roche) with TaqMan Pre-Developed Assay-on-demand
Gene Expression Reagent kits (Applied Biosystems) to analyze
mRNA levels for IFN-a1 (Hs00256882_s1), IFNb1(Hs00277188_
s1), IRF3 (Hs00155574_m1), IRF7 (Hs00242190_g1), STAT1
(Hs01014002_m1) and human GAPD (GAPDH) primer limited
endogenous control. Each sample was amplified in duplicate or
triplicate with a Roche Lightcycler sequence detector (Roche). The
relative amounts of cytokine mRNA were calculated with the
DDcomparative threshold (Ct) method, and mRNA levels were
normalized against GAPDH mRNA. The expression levels of each
gene were expressed as fold increase in infected cells at each time
point compared to non-treated cells. For exogenous interferon
induction cells were in addition pre-treated with IFN-aA/D
recombinant universal type I interferon 100 IU/ml (Sigma) and/or
anti-human interferon a/b receptor chain2 neutralizing antibody
(PBL) 16 h prior to infection.
Immunofluorescence and Microscopy
Cells were sorted and plated on 6-well plates or coverslips/LabTek
chambers(NUNC)respectivelyand16 hlaterinfectedwithadenovirus
at the moi 100 VP/cell. 1 h later the medium was changed to growth
medium containing 10% FCS. For virus internalization and TLR-
receptor studies cells were incubated with virus on ice for 30 min
washed with PBS and medium replaced with growth medium
containing 10% FCS. Cells were then washed and fixed with 4%
PFA10minRTandstoredat+4uCinPBS.Cellswerestainedwiththe
following primary antibodies: goat polyclonal anti-adenovirus hexon
(ViroStat), mouse monoclonal anti-TLR9 and TLR2 (Invivogen),
rabbit polyclonal anti-calnexin, rabbit polyclonal anti-EEA1, (Abcam),
mouse monoclonal anti-Oct3/4 (SantaCruz Biotechnology), rabbit
polyclonal anti-Musashi, rabbit polyclonal anti-MyD88 (Cell Signaling
Technology) and rat monoclonal anti-MyD88 (R&D Systems).
Alexa488, Alexa594 and Alexa647 conjugated secondary antibodies
were from Molecular Probes/Invitrogen. Cells were mounted with
Vectashield with conterstain for nucleai with 49,6 diamidino-2-
phenylindole (DAPI, Vectorlabs). For live cell imaging experiments
cells were treated and imaged as described in supplementary materials
and methods (Supplementary Materials and Methods S1).
Cells were visualized using Zeiss LSM 5 Duo laser scanning
confocal microscope (Jena, Germany). Images were processed for
presentation with Adobe Photoshop CS3 and Illustrator CS3
software (Adobe Systems, San Jose, CA).
Western blot
Cells were seeded at 7.5610
5 cells per well on 6-well plates
and infected with Ad5/3-Delta24 virus at moi 100. For
Figure 8. Constant STAT3 and STAT1 activation in non-CIC and no STAT1 activation in CIC. Western blot analysis of STAT1 and STAT3
shows stable upregulation and constant activation in ArLa non-CIC cells with a minor increase in response to infection in STAT1 (A). Jurkat cells
infected with Ad5/3-Delta24 are a positive control (A). (B) In JIMT-1 CD44
+/CD24
2/low CIC population there is constant expression of STAT1 however
no active P-STAT1 is detected up to 4 h. There is constant expression and activation of STAT3 in CD44
+/CD24
2/low CIC population up to 4 h (B). In
contrast in JIMT-1 CD44
2/CD24
2 non-CIC population there is decrease in the expression of STAT1 and STAT3 with a decrease also in P-STAT3 (B). ArLa
non-CICs do not respond to treatment with exogenous interferon as shown by no changes in STAT3 expression or activation (C).
doi:10.1371/journal.pone.0013859.g008
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interferon-aA/D 100 IU/ml (Sigma) was added to the infection
medium. After 30 min infection cell were harvested at respective
time points in CelLytic M lysis buffer (Sigma). Total protein was
measured with Bio-Rad Protein Assay (Bio-Rad) according to the
manufacturer’s protocol and 50 mg of total protein for each
sample were resolved on 4–20% SDS-PAGE gradient gel and
transferred onto a nitrocellulose membrane. Membranes were
incubated with primary antibodies 1 h at room temperature or
overnight at +4uC, followed by incubation with horse radish
peroxidase (HRP) conjugated secondary antibodies. Signal
detection was performed by enhanced chemiluminescence
( A m e r s h a m ) .P r i m a r ya n t i b o d i e s :S T A T 1 ,p h o s p h o - S T A T 1 ,
STAT3, phospho-STAT3 and SOCS3 (Cell Signaling Technol-
ogy), GAPDH (Zymed), SOCS1 (Millipore), Axl (Abcam),
MerTK (Novus Biologicals), Tyro3 (Santa Cruz Biotechnology)
and secondary antibodies anti-rabbit, anti-mouse and anti-goat
HRP (Sigma).
Figure 9. SOCS1, SOCS3 and TAM receptors in CIC and non-CIC. SOCS1, SOCS3 and TAM (Axl, Mer and Tyro3) receptor expression were
assayed by Western blot at different time points following infection in non-CIC ArLa cells and JIMT-1 CIC and non-CIC populations. The ArLa non-CIC
cells show upregulation of SOCS1 at 2 h and constant expression of SOCS3 with minor upregulation in response to adenovirus infection at 2 h (A). In
contrast there is constant expression of SOCS1 in both JIMT-1 CD44
+/CD24
2/low CIC infected and non-infected and infected CD44
2/CD24
2 non-CIC
populations at all time points (B) and non or minor expression of SOCS3 in both populations (B). No Axl, Mer or Tyro3 induction is seen in any time
point in ArLa non-CIC (C). Interestingly, JIMT-1 CD44
+/CD24
2/low CIC show constant upregulation of Axl, Mer and Tyro3 (D) in all time points and also
non-infected cells. Infected CD24
+ non-CIC population show constant Mer and variable Tyro3 expression but no Axl expression (D). Increased
inhibitory signaling is likely to contribute to dysfunction in innate immune responses in the CIC population.
doi:10.1371/journal.pone.0013859.g009
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Figure S1 Defective trafficking of TLR9 and MyD88 in JIMT-1
CD44
+/CD24
2/low CIC but not ArLa non-CIC. To further
investigate whether the localization of TLR9 in the JIMT-1
CD44
+/CD24
2/low CIC population was related to the trafficking
of the protein, we followed TLR9 and MyD88 in JIMT-1 CD44
+/
CD24
2/low CIC and ArLa non-CIC upon transient transfection of
constructs expressing fluorescently labeled proteins and organelle
markers and live cell imaging. Cells were sorted, transfected, and
infected the following day. Cells were then treated with
cycloheximide to stop protein synthesis and the fluorescently
labeled proteins were followed by live cell imaging for up to
6 hours. In JIMT-1 CD44
+/CD24
2/low CIC, at 4 h after
infection with Ad5/3-Delta24, transfected TLR9-YFP showed
retention in the ER-Golgi similarly to the endogenous protein (Fig.
S1A). Similarly the transfected MyD88-CFP, a cofactor of TLR
signaling, was also retained in the ER-Golgi and did not localize in
endosomes in JIMT-1 CD44
+/CD24
2/low CIC (Fig. S1B). In
ArLa non-CIC transfected TLR9-YFP and MyD88-CFP travel
through the Golgi at 1 h time point after infection (Fig. S1C) and
reach the endosomes at four hours after infection (Fig. S1D).
Found at: doi:10.1371/journal.pone.0013859.s001 (5.48 MB TIF)
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0013859.s002 (0.01 MB
DOCX)
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